

# IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

19 February 2021

## IBX Secures Additional Capital - Shareholders Exercise Options

**MELBOURNE** — Imagion Biosystems Limited (ASX: IBX) (the **Company** or **Imagion**) announces that it has received a total of \$299,829.62 for the exercise of options.

Comprised of \$60,954.50 for 1,219,090 Listed Options exercisable at 5 cents, expiring on 26 November 2021; \$155,047.95 for the exercise of 5,168,265 Listed Options exercisable at 3 cents, expiring on 28 April 2023; and \$83,827.17 for 2,986,604 Unlisted Options exercisable between 1.9 and 5.9 cents (weighted average of 2.8 cents).

The exercise of these options has resulted in the issue of 9,373,959 fully paid ordinary shares, as outlined in the attached application for quotation (Appendix 2A).

The capital structure of the Company following the exercise of these options is:

<b>Listed Securities</b>	
Fully Paid Ordinary Shares	1,026,884,180
Listed Options (IBXOA) exercisable at 3 cents and expiring 28 April 2023	240,395,582
Listed Options (IBXO) exercisable at 5 cents and expiring 26 November 2021	87,240,705
<b>Unlisted Securities</b>	
FY20 Performance Rights	10,000,000
FY20 Performance Options and Directors Options (exercisable at \$0.028 with expiry dates between 1 May 2026 and 1 May 2028)	8,500,000
FY20 Performance Options (exercisable at \$0.14 with expiry dates between 30 November 2026 and 30 November 2028)	3,000,000
Options (exercisable at \$0.028 on or before 24 June 2024)	2,150,000
Options (exercisable at \$0.20 on or before 20 June 2021)	3,000,000
Advisory Board Options (exercisable at \$0.06, vesting quarterly over two years and with varying expiry dates between 22 August 2024 and 7 October 2024)	600,000
Performance Options (exercisable at \$0.0909, vesting monthly over three years and with varying expiry dates between 30 September 2025 to 31 August 2028)	10,150,000
Performance Options (exercisable at \$0.175, vesting monthly over three years and with varying expiry dates between 28 February 2026 to 31 January 2029)	2,500,000

**-ENDS**

### About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

Imagion Biosystems Limited

ACN 616 305 027

Level 25, 525 Collins Street, Melbourne VIC 3000

[www.imagionbiosystems.com](http://www.imagionbiosystems.com)

For personal use only



**This Announcement has been approved by the Disclosure Committee of Imagion Biosystems Limited**

For further information please visit [www.imagionbiosystems.com](http://www.imagionbiosystems.com)

**U.S. Media Contact:**

Matthew Wygant

[matthew@biotechwriting.com](mailto:matthew@biotechwriting.com)

+1-408-905-7630

**Australian Media & Investor Relations:**

Kyahn Williamson, WE Communications

[We-AUImagionBiosystems@we-worldwide.com](mailto:We-AUImagionBiosystems@we-worldwide.com)

+61-3-9866-4722

For personal use only

## Appendix 2A

### Application for quotation of +securities

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

If you are an entity incorporated outside Australia and you are seeking quotation of a new class of +securities other than CDIs, you will need to obtain and provide an International Securities Identification Number (ISIN) for that class. Further information on the requirement for the notification of an ISIN is available from the Create Online Forms page. ASX is unable to create the new ISIN for non-Australian issuers.

\*Denotes minimum information required for first lodgement of this form, with exceptions provided in specific notes for certain questions. The balance of the information, where applicable, must be provided as soon as reasonably practicable by the entity.

#### Part 1 – Entity and announcement details

Question no	Question	Answer
1.1	*Name of entity We (the entity here named) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. <sup>1</sup>	IMAGION BIOSYSTEMS LIMITED
1.2	*Registration type and number <i>Please supply your ABN, ARSN, ARBN, ACN or another registration type and number (if you supply another registration type, please specify both the type of registration and the registration number).</i>	ACN 616305027
1.3	*ASX issuer code	IBX
1.4	*This announcement is <i>Tick whichever is applicable.</i>	<input checked="" type="checkbox"/> A new announcement <input type="checkbox"/> An update/amendment to a previous announcement <input type="checkbox"/> A cancellation of a previous announcement
1.4a	*Reason for update <i>Mandatory only if "Update" ticked in Q1.4 above. A reason must be provided for an update.</i>	N/A
1.4b	*Date of previous announcement to this update <i>Mandatory only if "Update" ticked in Q1.4 above.</i>	N/A
1.4c	*Reason for cancellation <i>Mandatory only if "Cancellation" ticked in Q1.4 above.</i>	N/A
1.4d	*Date of previous announcement to this cancellation <i>Mandatory only if "Cancellation" ticked in Q1.4 above.</i>	N/A

<sup>1</sup> Appendix 2A of the Listing Rules includes a warranty that an offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or 1012C(6) of the Corporations Act. If the securities to be quoted have been issued by way of a pro rata offer, to give this warranty, you will generally need to have lodged a cleansing notice with ASX under section 708AA(2)(f) or 1012DAA(2)(f) of the Corporations Act within 24 hours before the securities are offered (see ASIC Regulatory Guide 189 *Disclosure relief for rights issues*). If in doubt, please consult your legal adviser.

1.5	*Date of this announcement	19 February 2021
-----	----------------------------	------------------

## Part 2 – Type of issue

Question No.	Question	Answer
2.1	<p>*The +securities to be quoted are:</p> <p><i>Select whichever item is applicable.</i></p> <p><i>If you wish to apply for quotation of different types of issues of securities, please complete a separate Appendix 2A for each type of issue.</i></p>	<p><input type="checkbox"/> Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B</p> <p><input type="checkbox"/> Being issued under a +dividend or distribution plan</p> <p><input checked="" type="checkbox"/> Being issued as a result of options being exercised or other +convertible securities being converted</p> <p><input type="checkbox"/> Unquoted partly paid +securities that have been paid up and are now quoted fully paid +securities</p> <p><input type="checkbox"/> +Restricted securities where the escrow period has expired or is about to expire</p> <p><input type="checkbox"/> +Securities previously issued under an +employee incentive scheme where the restrictions on transfer have ceased or are about to cease</p> <p><input type="checkbox"/> +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer</p> <p><input type="checkbox"/> Other</p>
2.2a.1	<p>*Date of Appendix 3B notifying the market of the proposed issue of +securities for which quotation is now being sought</p> <p><i>Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B"</i></p>	N/A
2.2a.2	<p>*Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B?</p> <p><i>Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B".</i></p>	N/A

2.2a.2.1	<p>*Please provide details of the further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B</p> <p><i>Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.2a.2 is "Yes".</i></p> <p><i>Please provide details of the proposed dates and number of securities for the further issues. This may be the case, for example, if the Appendix 3B related to an accelerated pro rata offer with an institutional component being quoted on one date and a retail component being quoted on a later date.</i></p>	N/A
2.2b.1	<p>*Date of Appendix 3A.1 lodged with ASX in relation to the underlying +dividend or distribution</p> <p><i>Answer this question if your response to Q2.1 is "Being issued under a dividend or distribution plan".</i></p>	N/A
2.2b.2	<p>*Does the +dividend or distribution plan meet the requirement of listing rule 7.2 exception 4 that it does not impose a limit on participation?</p> <p><i>Answer this question if your response to Q2.1 is "Being issued under a dividend or distribution plan".</i></p> <p><i>Note: Exception 4 only applies where security holders are able to elect to receive all of their dividend or distribution as securities. For example, Exception 4 would not apply in the following circumstances: 1) The entity has specified a dollar limit on the level of participation e.g. security holders can only participate to a maximum value of \$x in respect of their entitlement, or 2) The entity has specified a maximum number of securities that can participate in the plan e.g. security holders can only receive securities in lieu of dividend payable for x number of securities.</i></p>	N/A

For personal use only

<p>2.2c.1</p>	<p>Please state the number and type of options that were exercised or other +convertible securities that were converted (including their ASX security code)</p> <p><i>Answer this question if your response to Q2.1 is "Being issued as a result of options being exercised or other convertible securities being converted".</i></p>	<ol style="list-style-type: none"> <li>1. 5,168,265 Listed Options exercisable at \$0.03 and expiring on 28 April 2023 (IBXOA)</li> <li>2. 1,219,090 Listed Options exercisable at \$0.05 and expiring on 26 November 2021 (IBXO)</li> <li>3. 198,063 Unlisted Options exercisable at \$0.0302 and expiring on 27 February 2021</li> <li>4. 183,950 Unlisted Options exercisable at \$0.0262 and expiring on 30 March 2021</li> <li>5. 304,951 Unlisted Options exercisable at \$0.0256 and expiring on 29 April 2021</li> <li>6. 377,602 Unlisted Options exercisable at \$0.0290 and expiring on 30 May 2021</li> <li>7. 952,987 Unlisted Options exercisable at \$0.0194 and expiring on 29 June 2021</li> <li>8. 129,425 Unlisted Options exercisable at \$0.0593 and expiring on 31 July 2021</li> <li>9. 243,651 Unlisted Options exercisable at \$0.0482 and expiring on 31 August 2021</li> <li>10. 101,499 Unlisted Options exercisable at \$0.0414 and expiring on 30 September 2021</li> <li>11. 187,384 Unlisted Options exercisable at \$0.0306 and expiring on 30 October 2021</li> <li>12. 140,351 Unlisted Options exercisable at \$0.0206 and expiring on 29 November 2021</li> <li>13. 166,741 Unlisted Options exercisable at \$0.0212 and expiring on 30 December 2021</li> </ol>
---------------	---	---

For personal use only

<p>2.2c.2</p>	<p>And the date the options were exercised or other +convertible securities were converted</p> <p><i>Answer this question if your response to Q2.1 is "Being issued as a result of options being exercised or other convertible securities being converted".</i></p> <p><i>Note: If this occurred over a range of dates, enter the date the last of the options was exercised or convertible securities was converted.</i></p>	<ol style="list-style-type: none"> <li>1. 322,987 Listed Options exercisable at \$0.03 and expiring on 28 April 2023 (IBXOA) converted on 5 February 2021</li> <li>2. 425,000 Listed Options exercisable at \$0.05 and expiring on 26 November 2021 (IXBO) converted on 5 February 2021</li> <li>3. 175,278 Listed Options exercisable at \$0.03 and expiring on 28 April 2023 (IBXOA) converted on 12 February 2021</li> <li>4. 684,090 Listed Options exercisable at \$0.05 and expiring on 28 April 2023 (IBXO) converted on 12 February 2021</li> <li>5. 4,670,000 Listed Options exercisable at \$0.03 and expiring on 28 April 2023 (IBXOA) converted on 18 February 2021</li> <li>6. 110,000 Listed Options exercisable at \$0.05 and expiring on 28 April 2023 (IBXO) converted on 18 February 2021</li> <li>7. 198,063 Unlisted Options exercisable at \$0.0302 and expiring on 27 February 2021 and converted on 15 February 2021</li> <li>8. 183,950 Unlisted Options exercisable at \$0.0262 and expiring on 30 March 2021 and converted on 15 February 2021</li> <li>9. 304,951 Unlisted Options exercisable at \$0.0256 and expiring on 29 April 2021 and converted on 15 February 2021</li> <li>10. 377,602 Unlisted Options exercisable at \$0.0290 and expiring on 30 May 2021 and converted on 15 February 2021</li> <li>11. 952,987 Unlisted Options exercisable at \$0.0194 and expiring on 29 June 2021 and converted on 15 February 2021</li> <li>12. 129,425 Unlisted Options exercisable at \$0.0593 and expiring on 31 July 2021 and converted on 15 February 2021</li> <li>13. 243,651 Unlisted Options exercisable at \$0.0482 and expiring on 31 August 2021 and converted on 15 February 2021</li> <li>14. 101,499 Unlisted Options exercisable at \$0.0414 and expiring on 30 September 2021 and converted on 15 February 2021</li> <li>15. 187,384 Unlisted Options exercisable at \$0.0306 and expiring</li> </ol>
---------------	--	--

For personal use only

		<p>on 30 October 2021 and converted on 15 February 2021</p> <p>16. 140,351 Unlisted Options exercisable at \$0.0206 and expiring on 29 November 2021 and converted on 15 February 2021</p> <p>17. 166,741 Unlisted Options exercisable at \$0.0212 and expiring on 30 December 2021 and converted on 15 February 2021</p>
2.2d.1	<p>Please state the number and type of partly paid +securities (including their ASX security code) that were fully paid up</p> <p><i>Answer this question if your response to Q2.1 is "Unquoted partly paid securities that have been paid up and are now quoted fully paid securities".</i></p>	N/A
2.2d.2	<p>And the date the +securities were fully paid up</p> <p><i>Answer this question if your response to Q2.1 is "Unquoted partly paid securities that have been paid up and are now quoted fully paid securities".</i></p> <p><i>Note: If this occurred over a range of dates, enter the date the last of the securities was fully paid up.</i></p>	N/A
2.2e.1	<p>Please state the number and type of +restricted securities (including their ASX security code) where the escrow period has expired or is about to expire</p> <p><i>Answer this question if your response to Q2.1 is "Restricted securities where the escrow period has expired or is about to expire".</i></p>	N/A
2.2e.2	<p>And the date the escrow restrictions have ceased or will cease</p> <p><i>Answer this question if your response to Q2.1 is "Restricted securities where the escrow period has expired or is about to expire".</i></p> <p><i>Note: If this occurred over a range of dates, enter the date the last of the escrow restrictions has ceased or will cease.</i></p>	N/A
2.2f.1	<p>Please state the number and type of +securities (including their ASX security code) previously issued under the +employee incentive scheme where the restrictions on transfer have ceased or are about to cease</p> <p><i>Answer this question if your response to Q2.1 is "Securities previously issued under an employee incentive scheme where the restrictions on transfer have ceased or are about to cease".</i></p>	N/A
2.2f.2	<p>And the date the restrictions on transfer have ceased or will cease:</p> <p><i>Answer this question if your response to Q2.1 is "Securities previously issued under an employee incentive scheme where the restrictions on transfer have ceased or are about to cease".</i></p> <p><i>Note: If this occurred over a range of dates, enter the date the last of the restrictions on transfer has ceased or will cease.</i></p>	N/A

For personal use only



2.2g.1	<p>Please state the number and type of +securities (including their ASX security code) issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer</p> <p><i>Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer".</i></p>	N/A						
2.2g.2	<p>*Please attach a document or provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms.</p> <p><i>Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer".</i></p>	N/A						
2.2g.3	<p>*Are any of these +securities being issued to +key management personnel (KMP) or an +associate</p> <p><i>Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer".</i></p>	N/A						
2.2g.3.a	<p>*Provide details of the recipients and the number of +securities issued to each of them.</p> <p><i>Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer" and your response to Q2.2g.3 is "Yes". Repeat the detail in the table below for each KMP involved in the issue. If the securities are being issued to the KMP, repeat the name of the KMP or insert "Same" in "Name of registered holder". If the securities are being issued to an associate of a KMP, insert the name of the associate in "Name of registered holder".</i></p> <table border="1" data-bbox="338 1330 1404 1458"> <thead> <tr> <th data-bbox="338 1330 606 1406">Name of KMP</th> <th data-bbox="606 1330 874 1406">Name of registered holder</th> <th data-bbox="874 1330 1404 1406">Number of +securities</th> </tr> </thead> <tbody> <tr> <td data-bbox="338 1406 606 1458"></td> <td data-bbox="606 1406 874 1458"></td> <td data-bbox="874 1406 1404 1458"></td> </tr> </tbody> </table>		Name of KMP	Name of registered holder	Number of +securities			
Name of KMP	Name of registered holder	Number of +securities						
2.2h.1	<p>*The purpose(s) for which the entity is issuing the +securities is:</p> <p><i>Answer this question if your response to Q2.1 is "Other".</i></p> <p><i>You may select one or more of the items in the list.</i></p>	<p><input type="checkbox"/> To raise additional working capital</p> <p><input type="checkbox"/> To fund the retirement of debt</p> <p><input type="checkbox"/> To pay for the acquisition of an asset [provide details below]</p> <p><input type="checkbox"/> To pay for services rendered [provide details below]</p> <p><input type="checkbox"/> Other [provide details below]</p> <p><i>Additional details:</i></p>						

For personal use only

2.2h.2	<p>*Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including (if applicable) why the issue of the +securities has not been previously announced to the market in an Appendix 3B</p> <p><i>You must answer this question if your response to Q2.1 is "Other". If there is no other information to provide, please answer "Not applicable" or "N/A".</i></p>	N/A
2.2i	<p>*Are these +securities being offered under a +disclosure document or +PDS?</p> <p><i>Answer this question if your response to Q2.1 is any option other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B".</i></p>	N/A
2.2i.1	<p>*Date of +disclosure document or +PDS?</p> <p><i>Answer this question if your response to Q2.1 is any option other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.2i is "Yes".</i></p> <p><i>Under the Corporations Act, the entity must apply for quotation of the securities within 7 days of the date of the disclosure document or PDS.</i></p>	N/A
2.3	<p>*The +securities to be quoted are:</p> <p><i>Tick whichever is applicable</i></p>	<p><input checked="" type="checkbox"/> Additional +securities in a class that is already quoted on ASX ("existing class")</p> <p><input type="checkbox"/> New +securities in a class that is not yet quoted on ASX ("new class")</p>

### Part 3A – number and type of +securities to be quoted (existing class or new class) where issue has previously been notified to ASX in an Appendix 3B

*Answer the questions in this Part if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.3 is "existing class" or "new class".*

Question No.	Question	Answer
3A.1	*ASX security code & description	N/A
3A.2	*Number of +securities to be quoted	N/A

### Part 3B – number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

*Answer the questions in this Part if your response to Q2.1 is anything other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.3 is "existing class".*

Question No.	Question	Answer
3B.1	*ASX security code & description	Fully Paid Ordinary Shares, IBX
3B.2	*Number of +securities to be quoted	9,373,959

3B.3a	*Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?	Yes
3B.3b	*Is the actual date from which the +securities will rank equally (non-ranking end date) known? <i>Answer this question if your response to Q3B.3a is "No".</i>	N/A
3B.3c	*Provide the actual non-ranking end date <i>Answer this question if your response to Q3B.3a is "No" and your response to Q3B.3b is "Yes".</i>	N/A
3B.3d	*Provide the estimated non-ranking end period <i>Answer this question if your response to Q3B.3a is "No" and your response to Q3B.3b is "No".</i>	N/A
3B.3e	*Please state the extent to which the +securities do not rank equally: <ul style="list-style-type: none"> <li>• in relation to the next dividend, distribution or interest payment; or</li> <li>• for any other reason</li> </ul> <i>Answer this question if your response to Q3B.3a is "No".</i> <i>For example, the securities may not rank at all, or may rank proportionately based on the percentage of the period in question they have been on issue, for the next dividend, distribution or interest payment; or they may not be entitled to participate in some other event, such as an entitlement issue.</i>	N/A

### Part 3C – number and type of +securities to be quoted (new class) where issue has not previously been notified to ASX in an Appendix 3B

Answer the questions in this Part if your response to Q2.1 is anything other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.3 is "new class".

Question No.	Question	Answer
3C.1	*Security description	N/A
3C.2	*Security type <i>Select one item from the list that best describes the securities the subject of this form. This will determine more detailed questions to be asked about the security later in this section. Select "ordinary fully or partly paid shares/units" for stapled securities or CDIs. For interest rate securities, please select the appropriate choice from either "Convertible debt securities" or "Non-convertible debt securities". Select "Other" for performance shares/units and performance options/rights or if the selections available in the list do not appropriately describe the security being issued.</i>	<input type="checkbox"/> Ordinary fully or partly paid shares/units <input type="checkbox"/> Options <input type="checkbox"/> +Convertible debt securities <input type="checkbox"/> Non-convertible +debt securities <input type="checkbox"/> Redeemable preference shares/units <input type="checkbox"/> Other
3C.3	ISIN code <i>Answer this question if you are an entity incorporated outside Australia and you are seeking quotation of a new class of securities other than CDIs. See also the note at the top of this form.</i>	N/A
3C.4	*Number of +securities to be quoted	N/A

3C.5a	*Will all the +securities issued in this class rank equally in all respects from the issue date?	N/A
3C.5b	*Is the actual date from which the +securities will rank equally (non-ranking end date) known? <i>Answer this question if your response to Q3C.5a is "No".</i>	N/A
3C.5c	*Provide the actual non-ranking end date <i>Answer this question if your response to Q3C.5a is "No" and your response to Q3C.5b is "Yes".</i>	N/A
3C.5d	*Provide the estimated non-ranking end period <i>Answer this question if your response to Q3C.5a is "No" and your response to Q3C.5b is "No".</i>	N/A
3C.5e	*Please state the extent to which the +securities do not rank equally: <ul style="list-style-type: none"> <li>• in relation to the next dividend, distribution or interest payment; or</li> <li>• for any other reason</li> </ul> <i>Answer this question if your response to Q3C.5a is "No".</i> <i>For example, the securities may not rank at all, or may rank proportionately based on the percentage of the period in question they have been on issue, for the next dividend, distribution or interest payment; or they may not be entitled to participate in some other event, such as an entitlement issue.</i>	N/A
3C.6	Please attach a document or provide a URL link for a document lodged with ASX setting out the material terms of the +securities to be quoted <i>You may cross-reference a disclosure document, PDS, information memorandum, investor presentation or other announcement with this information provided it has been released to the ASX Market Announcements Platform.</i>	N/A
3C.7	*Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1? <i>Answer this question only if you are an ASX Listing. (ASX Foreign Exempt Listings and ASX Debt Listings do not have to answer this question).</i> <i>If your response is "No" and the securities have any unusual terms, you should approach ASX as soon as possible for confirmation under listing rule 6.1 that the terms are appropriate and equitable.</i>	N/A

3C.8	*Provide a distribution schedule for the new +securities according to the categories set out in the left hand column – including the number of recipients and the total percentage of the new +securities held by the recipients in each category.	
	Number of +securities held	Number of holders
	1 – 1,000	
	1,001 – 5,000	
	5,001 – 10,000	
	10,001 – 100,000	
	100,001 and over	
<p><i>Answer this question only if you are an ASX Listing (ASX Foreign Exempt Listings and ASX Debt Listings do not have to answer this question) and the securities to be quoted have already been issued.</i></p> <p><i>Note: if the securities to be quoted have not yet been issued, under listing rule 3.10.5, you will need to provide to ASX a list of the 20 largest recipients of the new +securities, and the number and percentage of the new +securities received by each of those recipients, and a distribution schedule for the securities when they are issued.</i></p>		
3C.9a	<b>Ordinary fully or partly paid shares/units details</b>	
<i>Answer the questions in this section if you selected this security type in your response to Question 3C.2.</i>		
	*+Security currency <i>This is the currency in which the face amount of an issue is denominated. It will also typically be the currency in which distributions are declared.</i>	N/A
	*Will there be CDIs issued over the +securities?	N/A
	*CDI ratio <i>Answer this question if you answered “Yes” to the previous question. This is the ratio at which CDIs can be transmuted into the underlying security (e.g. 4:1 means 4 CDIs represent 1 underlying security whereas 1:4 means 1 CDI represents 4 underlying securities).</i>	N/A
	*Is it a partly paid class of +security?	Yes or No
	*Paid up amount: unpaid amount <i>Answer this question if answered “Yes” to the previous question.</i> <i>The paid up amount represents the amount of application money and/or calls which have been paid on any security considered ‘partly paid’</i> <i>The unpaid amount represents the unpaid or yet to be called amount on any security considered ‘partly paid’.</i> <i>The amounts should be provided per the security currency (e.g. if the security currency is AUD, then the paid up and unpaid amount per security in AUD).</i>	N/A
	*Is it a stapled +security? <i>This is a security class that comprises a number of ordinary shares and/or ordinary units issued by separate entities that are stapled together for the purposes of trading.</i>	N/A
3C.9b	<b>Option details</b>	
<i>Answer the questions in this section if you selected this security type in your response to Question 3C.2.</i>		
	*+Security currency <i>This is the currency in which the exercise price is payable.</i>	N/A

	<p><b>*Exercise price</b> <i>The price at which each option can be exercised and convert into the underlying security.</i> <i>The exercise price should be provided per the security currency (i.e. if the security currency is AUD, the exercise price should be expressed in AUD).</i></p>	N/A
	<p><b>*Expiry date</b> <i>The date on which the options expire or terminate.</i></p>	N/A
	<p><b>*Details of the number and type of +security (including its ASX security code if the +security is quoted on ASX) that will be issued if an option is exercised</b> <i>For example, if the option can be exercised to receive one fully paid ordinary share with ASX security code ABC, please insert "One fully paid ordinary share (ASX:ABC)".</i></p>	N/A
3C.9c	<p><b>Details of non-convertible +debt securities, +convertible debt securities, or redeemable preference shares/units</b> <i>Answer the questions in this section if you selected one of these security types in your response to Question 3C.2.</i> <i>Refer to Guidance Note 34 and the "Guide to the Naming Conventions and Security Descriptions for ASX Quoted Debt and Hybrid Securities" for further information on certain terms used in this section</i></p>	
	<p><b>*Type of +security</b> <i>Select one item from the list</i></p>	<input type="checkbox"/> Simple corporate bond <input type="checkbox"/> Non-convertible note or bond <input type="checkbox"/> Convertible note or bond <input type="checkbox"/> Preference share/unit <input type="checkbox"/> Capital note <input type="checkbox"/> Hybrid security <input type="checkbox"/> Other
	<p><b>*+Security currency</b> <i>This is the currency in which the face value of the security is denominated. It will also typically be the currency in which interest or distributions are paid.</i></p>	N/A
	<p><b>Face value</b> <i>This is the principal amount of each security.</i> <i>The face value should be provided per the security currency (i.e. if security currency is AUD, then the face value per security in AUD).</i></p>	N/A
	<p><b>*Interest rate type</b> <i>Select one item from the list</i> <i>Select the appropriate interest rate type per the terms of the security. Definitions for each type are provided in the Guide to the Naming Conventions and Security Descriptions for ASX Quoted Debt and Hybrid Securities</i></p>	<input type="checkbox"/> Fixed rate <input type="checkbox"/> Floating rate <input type="checkbox"/> Indexed rate <input type="checkbox"/> Variable rate <input type="checkbox"/> Zero coupon/no interest <input type="checkbox"/> Other
	<p><b>Frequency of coupon/interest payments per year</b> <i>Select one item from the list.</i></p>	<input type="checkbox"/> Monthly <input type="checkbox"/> Quarterly <input type="checkbox"/> Semi-annual <input type="checkbox"/> Annual <input type="checkbox"/> No coupon/interest payments <input type="checkbox"/> Other
	<p><b>First interest payment date</b></p>	N/A

For personal use only

	<i>A response is not required if you have selected "No coupon/interest payments" in response to the question above on the frequency of coupon/interest payments</i>	
	Interest rate per annum <i>Answer this question if the interest rate type is fixed.</i>	N/A
	*Is the interest rate per annum estimated at this time? <i>Answer this question if the interest rate type is fixed.</i>	N/A
	If the interest rate per annum is estimated, then what is the date for this information to be announced to the market (if known) <i>Answer this question if the interest rate type is fixed and your response to the previous question is "Yes". Answer "Unknown" if the date is not known at this time.</i>	N/A
	*Does the interest rate include a reference rate, base rate or market rate (e.g. BBSW or CPI)? <i>Answer this question if the interest rate type is floating or indexed.</i>	N/A
	*What is the reference rate, base rate or market rate? <i>Answer this question if the interest rate type is floating or indexed and your response to the previous question is "Yes".</i>	N/A
	*Does the interest rate include a margin above the reference rate, base rate or market rate? <i>Answer this question if the interest rate type is floating or indexed.</i>	N/A
	*What is the margin above the reference rate, base rate or market rate (expressed as a percent per annum) <i>Answer this question if the interest rate type is floating or indexed and your response to the previous question is "Yes".</i>	N/A.
	*S128F of the Income Tax Assessment Act status applicable to the +security <i>Select one item from the list For financial products which are likely to give rise to a payment to which s128F of the Income Tax Assessment Act applies, ASX requests issuers to confirm the s128F status of the security:</i> <ul style="list-style-type: none"> <li>• "s128F exempt" means interest payments are not taxable to non-residents;</li> <li>• "Not s128F exempt" means interest payments are taxable to non-residents;</li> <li>• "s128F exemption status unknown" means the issuer is unable to advise the status;</li> <li>• "Not applicable" means s128F is not applicable to this security</li> </ul>	<input type="checkbox"/> s128F exempt <input type="checkbox"/> Not s128F exempt <input type="checkbox"/> s128F exemption status unknown <input type="checkbox"/> Not applicable
	*Is the +security perpetual (i.e. no maturity date)?	N/A
	*Maturity date <i>Answer this question if the security is not perpetual</i>	N/A

	<p>*Select other features applicable to the +security</p> <p><i>Up to 4 features can be selected. Further information is available in the Guide to the Naming Conventions and Security Descriptions for ASX Quoted Debt and Hybrid Securities.</i></p>	<input type="checkbox"/> Simple <input type="checkbox"/> Subordinated <input type="checkbox"/> Secured <input type="checkbox"/> Converting <input type="checkbox"/> Convertible <input type="checkbox"/> Transformable <input type="checkbox"/> Exchangeable <input type="checkbox"/> Cumulative <input type="checkbox"/> Non-Cumulative <input type="checkbox"/> Redeemable <input type="checkbox"/> Extendable <input type="checkbox"/> Reset <input type="checkbox"/> Step-Down <input type="checkbox"/> Step-Up <input type="checkbox"/> Stapled <input type="checkbox"/> None of the above
	<p>*Is there a first trigger date on which a right of conversion, redemption, call or put can be exercised (whichever is first)?</p>	N/A
	<p>*If yes, what is the first trigger date</p> <p><i>Answer this question if your response to the previous question is "Yes".</i></p>	N/A
	<p>Details of the number and type of +security (including its ASX security code if the +security is quoted on ASX) that will be issued if the +securities to be quoted are converted, transformed or exchanged</p> <p><i>Answer this question if the security features include "converting", "convertible", "transformable" or "exchangeable".</i></p> <p><i>For example, if the security can be converted into 1,000 fully paid ordinary shares with ASX security code ABC, please insert "1,000 fully paid ordinary shares (ASX:ABC)".</i></p>	N/A

#### Part 4 – Issue details

Question No.	Question	Answer
4.1	*Have the +securities to be quoted been issued yet?	Yes



<p>4.1a</p>	<p>*What was their date of issue? <i>Answer this question if your response to Q4.1 is "Yes".</i></p>	<ol style="list-style-type: none"> <li>1. 322,987 Listed Options exercisable at \$0.03 and expiring on 28 April 2023 (IBXOA) converted on 5 February 2021</li> <li>2. 425,000 Listed Options exercisable at \$0.05 and expiring on 26 November 2021 (IXBO) converted on 5 February 2021</li> <li>3. 175,278 Listed Options exercisable at \$0.03 and expiring on 28 April 2023 (IBXOA) converted on 12 February 2021</li> <li>4. 684,090 Listed Options exercisable at \$0.05 and expiring on 28 April 2023 (IBXO) converted on 12 February 2021</li> <li>5. 4,670,000 Listed Options exercisable at \$0.03 and expiring on 28 April 2023 (IBXOA) converted on 18 February 2021</li> <li>6. 110,000 Listed Options exercisable at \$0.05 and expiring on 28 April 2023 (IBXO) converted on 18 February 2021</li> <li>7. 198,063 Unlisted Options exercisable at \$0.0302 and expiring on 27 February 2021 and converted on 15 February 2021</li> <li>8. 183,950 Unlisted Options exercisable at \$0.0262 and expiring on 30 March 2021 and converted on 15 February 2021</li> <li>9. 304,951 Unlisted Options exercisable at \$0.0256 and expiring on 29 April 2021 and converted on 15 February 2021</li> <li>10. 377,602 Unlisted Options exercisable at \$0.0290 and expiring on 30 May 2021 and converted on 15 February 2021</li> <li>11. 952,987 Unlisted Options exercisable at \$0.0194 and expiring on 29 June 2021 and converted on 15 February 2021</li> <li>12. 129,425 Unlisted Options exercisable at \$0.0593 and expiring on 31 July 2021 and converted on 15 February 2021</li> <li>13. 243,651 Unlisted Options exercisable at \$0.0482 and expiring on 31 August 2021 and converted on 15 February 2021</li> <li>14. 101,499 Unlisted Options exercisable at \$0.0414 and expiring on 30 September 2021 and converted on 15 February 2021</li> <li>15. 187,384 Unlisted Options exercisable at \$0.0306 and expiring</li> </ol>
-------------	--	--

For personal use only

		<p>on 30 October 2021 and converted on 15 February 2021</p> <p>16. 140,351 Unlisted Options exercisable at \$0.0206 and expiring on 29 November 2021 and converted on 15 February 2021</p> <p>17. 166,741 Unlisted Options exercisable at \$0.0212 and expiring on 30 December 2021 and converted on 15 February 2021</p>
4.1b	<p>*What is their proposed date of issue? <i>Answer this question if your response to Q4.1 is "No".</i></p>	N/A
4.2	<p>*Are the +securities to be quoted being issued for a cash consideration? <i>If the securities are being issued for nil cash consideration, answer this question "No".</i></p>	Yes
4.2a	<p>*In what currency is the cash consideration being paid <i>For example, if the consideration is being paid in Australian Dollars, state AUD. Answer this question if your response to Q4.2 is "Yes".</i></p>	AUD
4.2b	<p>*What is the issue price per +security <i>Answer this question if your response to Q4.2 is "Yes" and by reference to the issue currency provided in your response to Q4.2a. Note: you cannot enter a nil amount here. If the securities are being issued for nil cash consideration, answer Q4.2 as "No" and complete Q4.2c and Q4.2d.</i></p>	<ol style="list-style-type: none"> <li>1. 5,168,265 Shares at \$0.03 per share</li> <li>2. 1,219,090 Shares at \$0.05 per share</li> <li>3. 198,063 Shares at \$0.0302 per share</li> <li>4. 183,950 Shares at \$0.0262 per share</li> <li>5. 304,951 Shares at \$0.0256 per share</li> <li>6. 377,602 Shares at \$0.0290 per share</li> <li>7. 952,987 Shares at \$0.0194 per share</li> <li>8. 129,425 Shares at \$0.0593 per share</li> <li>9. 243,651 Shares at \$0.0482 per share</li> <li>10. 101,499 Shares at \$0.0414 per share</li> <li>11. 187,384 Shares at \$0.0306 per share</li> <li>12. 140,351 Shares at \$0.0206 per share</li> <li>13. 166,741 Shares at \$0.0212 per share</li> </ol>
4.2c	<p>Please describe the consideration being provided for the +securities to be quoted <i>Answer this question if your response to Q4.2 is "No".</i></p>	N/A

For personal use only

4.2d	Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted <i>Answer this question if your response to Q4.2 is "No".</i>	N/A
4.3	Any other information the entity wishes to provide about the issue	N/A

## Part 5 – Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

*Note: the figures provided in the tables in sections 5.1 and 5.2 below are used to calculate the total market capitalisation of the entity published by ASX from time to time. Please make sure you include in the relevant table each class of securities issued by the entity.*

*If you have quoted CHES Depository Interests (CDIs) issued over your securities, include them in the table in section 5.1 and include in the table in section 5.2 any securities that do not have CDIs issued over them (and therefore are not quoted on ASX).*

*Restricted securities should only be included in the table in section 5.1 if you are applying to have them quoted because the escrow period for the securities has expired or is about to expire. Otherwise include them in the table in section 5.2.*

5.1	<b>*Quoted +securities</b> (total number of each +class of +securities quoted on ASX following the +quotation of the +securities the subject of this application)	
	ASX security code and description	Total number of +securities on issue
	IBX – Fully Paid Ordinary Shares	1,026,884,180
	IBXO – Listed Options (exercisable at \$0.05 on or before 26 November 2021)	87,240,705
	IBXOA – Listed Options (exercisable at \$0.03 on or before 28 April 2023)	240,395,582
5.2	<b>*Unquoted +securities</b> (total number of each +class of +securities issued but not quoted on ASX):	
	ASX security code and description	Total number of +securities on issue
	FY20 Performance Rights*	10,000,000
	FY20 Performance Options and Director Options (exercisable at \$0.028 with expiry dates between 1 May 2026 and 1 May 2028)*	8,500,000
	FY20 Performance Options (exercisable at \$0.14 with expiry dates between 30 November 2026 and 30 November 2028)	3,000,000
	Options (exercisable at \$0.028 on or before 24 June 2024)*	2,150,000
	Options (exercisable at \$0.20 on or before 20 June 2021)*	3,000,000
	Advisory Board Options (exercisable at \$0.06, vesting quarterly over two years and with varying expiry dates between 22 August 2024 and 7 October 2024)*	600,000
	Performance Options (exercisable at \$0.0909, vesting monthly over three years and with varying expiry dates between 30 September 2025 to 31 August 2028)*	10,150,000
	Performance Options (exercisable at \$0.175, vesting monthly over three years and with varying expiry dates between 28 February 2026 to 31 January 2029)*	2,500,000
	* See <b>Schedule 1</b> for breakdown of Unquoted Securities	

## Part 6 – Other Listing Rule requirements

The questions in this Part should only be answered if you are an ASX Listing (ASX Foreign Exempt Listings and ASX Debt Listings do not need to complete this Part) and:

- your response to Q2.1 is "Being issued under a dividend/distribution plan" and the response to Q2.2b.2 is "No"; or
- your response to Q2.1 is "Other".

Note that if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B", it is assumed that you will have provided the information referred to in this Part in the Appendix 3B.

Question No.	Question	Answer
6.1	*Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?	No – rule 7.1 and rule 7.1A do not apply under Listing Rule 7.2, exception 13 – as the options were issued in compliance with listing rules when issued.
6.1a	*Date of meeting or proposed meeting to approve the issue under listing rule 7.1 <i>Answer this question if the response to Q6.1 is "Yes".</i>	N/A
6.1b	*Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? <i>Answer this question if the response to Q6.1 is "No".</i>	N/A
6.1b.1	*How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? <i>Answer this question if the response to Q6.1 is "No" and the response to Q6.1b is "Yes".</i> <i>Please complete and separately send by email to your ASX listings adviser a work sheet in the form of Annexure B to Guidance Note 21 confirming the entity has the available capacity under listing rule 7.1 to issue that number of securities.</i>	N/A
6.1c	*Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? <i>Answer this question if the response to Q6.1 is "No".</i>	N/A
6.1c.1	*How many +securities are being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A? <i>Answer this question if the response to Q6.1 is "No" and the response to Q6.1c is "Yes".</i> <i>Please complete and separately send by email to your ASX listings adviser a work sheet in the form of Annexure C to Guidance Note 21 confirming the entity has the available capacity under listing rule 7.1A to issue that number of securities.</i>	N/A

Introduced 01/12/19, amended 31/01/20

For personal use only

## SCHEDULE 1 - Unquoted Securities

IMAGION BIOSYSTEMS LIMITED  
ACN 616305027

ISO Options \$0.028 Exp 24 June 2024	2,150,000
Performance Rights Vesting on or before 30 April 2023	5,000,000
Performance Rights Vesting on or before 30 November 2023	5,000,000
Unlisted Options \$0.028 Vesting 1 May 2021 Exp 1 May 2026	3,250,000
Unlisted Options \$0.028 Vesting 1 May 2023 Exp 1 May 2028	2,000,000
Unlisted Options \$0.028 vesting 1 May 2022 Exp 1 May 2027	3,250,000
Unlisted Options \$0.14 vesting 30 November 2021 Exp 30 November 2026	1,000,000
Unlisted Options \$0.14 vesting 30 November 2022 Exp 30 November 2027	1,000,000
Unlisted Options \$0.14 vesting 30 November 2023 Exp 30 November 2028	1,000,000
Unlisted Options exercise \$0.06 exp 20 September 2024	100,000
Unlisted Options exercise \$0.06 exp 22 August 2024	300,000
Unlisted Options exercise \$0.06 exp 7 October 2024	200,000
Unlisted Options exercise \$0.20 exp 20 June 2021	3,000,000
Unlisted Performance Options - \$0.0909 Exp between 30.09.2025 - 31.08.2028	10,150,000
Unlisted Performance Options - \$0.175 Exp between 28 Feb 2026 – 31 Jan 2029	2,500,000
<b>Total Unquoted Options</b>	<b>39,900,000</b>

For personal use only